MabSpace and Hengrui link up to develop novel antibody therapeutics

MabSpace will discover and select humanised lead antibodies, while Hengrui will receive exclusive global rights to the resulting therapeutic candidates

Hong Kong-based biotechnology company-MabSpace Biosciences has signed a contract with Chinese pharmaceutical company Jiangsu Hengrui Medicine Co, to jointly develop novel antibody therapeutics on two targets.

Under the agreement, MabSpace will be responsible for the discovery and selection of humanised lead antibodies, while Hengrui will receive exclusive global rights to the resulting therapeutic candidates for the nominated targets, and will further develop the selected candidates.

Companies